GlassScriptPhysician profile
Lindsay Curtis
NPI 1447411699
$1,707.96
in general payments reported to CMS, 2019-2025
28 companies · $457 in 2025
The $457 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $402 · 2023: $429 · 2024: $420 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291 · Entertainment: $14.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.45 |
| Entertainment | $14.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $273.29 | 2022-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Mayne Pharma Commercial LLC | $220.72 | 2022-2025 | |
| Sage Therapeutics, LLC | $197.34 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $127.59 | 2022-2023 | Summit Doppler |
| Sumitomo Pharma America, INC. | $115.16 | 2023 | Gemtesa, Myfembree |
| Daiichi Sankyo INC. | $102.58 | 2024-2025 | Injectafer |
| Pfizer INC. | $72.67 | 2023-2025 | |
| Organon LLC | $65.98 | 2022-2024 | |
| Exeltis, USA INC. | $53.78 | 2023-2024 | Slynd |
| Astellas Pharma US INC | $52.90 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $50.59 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $47.40 | 2025 | Qelbree |
| Meditrina | $35.56 | 2025 | |
| Myovant Sciences INC. | $29.03 | 2022 | |
| Axonics, INC. | $27.05 | 2023 | Axonics |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $25.46 | 2024 | Perclot |
| Ethicon US, LLC | $25.38 | 2024 | Enseal |
| Channel Medsystems, INC. | $22.08 | 2023 | |
| Boston Scientific Corporation | $20.52 | 2024 | Wavewriter Alpha Prime 16 |
| Shield Therapeutics INC | $19.32 | 2023 | Accrufer |
| Biogen, INC. | $18.36 | 2023 | Spinraza |
| Duchesnay USA Incorporated | $18.03 | 2022 | |
| Hologic Sales and Service, LLC | $16.49 | 2024 | Aptima |
| Olympus America INC. | $16.03 | 2023 | Olympus |
| Provepharm INC. | $14.48 | 2024 | Bludigo |
| Urovant Sciences INC | $14.26 | 2022 | |
| Smith+Nephew, INC. | $13.89 | 2025 | Pico 14 |
| Medtronic, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.